ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) announced a favorable court ruling on Friday.
The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia’s ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson’s Disease Psychosis.
The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers.
“We are very pleased with today’s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,” said Catherine …
Full story available on Benzinga.com
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) announced a favorable court ruling on Friday.
The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia’s ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson’s Disease Psychosis.
The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers.
“We are very pleased with today’s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,” said Catherine …
Full story available on Benzinga.com
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) announced a favorable court ruling on Friday.
The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia’s ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson’s Disease Psychosis.
The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers.
“We are very pleased with today’s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,” said Catherine …Full story available on Benzinga.com Read MoreACAD, News, PT Changes, Price Target, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, ACAD, US0042251084, News, Price Target, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, Benzinga Markets
